戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ell wall-active agents (e.g., vancomycin and bacitracin).
2     The latter clone exhibited resistance to bacitracin.
3 d by p-chloromercuribenzenesulfonic acid and bacitracin.
4 ibution of the nonpolar amino acids found in bacitracin.
5 enged with the lipid II cycle-inhibiting AMP bacitracin.
6 d by other nephrotoxicants such as CdCl2 and bacitracin.
7 action, which was found to be independent of bacitracin.
8 a-PG and Lys-PG and increased sensitivity to bacitracin.
9  the genes encoding pilus in the presence of bacitracin.
10 , such as vancomycin, ramoplanin, nisin, and bacitracin.
11 ol of sigmaX and sigmaM, was also induced by bacitracin.
12 train had an eightfold-higher sensitivity to bacitracin.
13 verine (20 microM), methylamine (20 mM), and bacitracin (2 mg/ml) prevented cell pair formation even
14 l transmission with the use of PDI inhibitor bacitracin (98.21%/92.48% reduction in intensity/prevale
15 tal-binding amino acids of angiotensin I and bacitracin A are oxidized, while no oxidation is observe
16 te of bacitracin A with (1)O2 decreased upon bacitracin A coordination with Zn(2+), demonstrating tha
17      Furthermore, the photooxidation rate of bacitracin A with (1)O2 decreased upon bacitracin A coor
18 lly shifted (1)H NMR features concludes that bacitracin A(1), the most potent component of the bacitr
19  by (1)O2 is a major degradation pathway for bacitracin A, the most potent congener of the mixture.
20 crystal structure for the ternary complex of bacitracin A, zinc, and a geranyl-pyrophosphate ligand a
21  high-potent bacitracin analogues, including bacitracins A(1), B(1), and B(2), are virtually identica
22 es with low antibiotic activities, including bacitracins A(2) and F.
23  shedding induced by PDI-blocking Abs and by bacitracin, a known inhibitor of PDI activity, and direc
24                      Despite the wide use of bacitracin, a structure-activity relationship for this d
25 udies have shown that when bound to C(55)PP, bacitracin adopts a highly ordered amphipathic conformat
26 thesis, leads to an increased sensitivity to bacitracin, an antibiotic that binds undecaprenyl pyroph
27  report the response of Bacillus subtilis to bacitracin, an inhibitor of cell wall biosynthesis found
28                                              Bacitracin, an inhibitor of plasma membrane oxidoreducta
29                                              Bacitracin, an inhibitor of the reductive function of th
30  structure of the metal complexes of several bacitracin analogues by the use of paramagnetic Co(II) a
31  thiazoline ring does not bind Co(II) in the bacitracin analogues with low antibiotic activities, inc
32 gned, synthesized, and evaluated a series of bacitracin analogues, a number of which were found to ex
33 1)H NMR spectral features of the high-potent bacitracin analogues, including bacitracins A(1), B(1),
34 boxylation is inhibited by the PDI inhibitor bacitracin and also by small interfering RNA silencing o
35 he development of DAP-R and elevated MICs to bacitracin and ceftriaxone.
36 ant was also significantly more sensitive to bacitracin and lysozyme than the wild type in in vitro c
37 mutans streptococci (MS) on mitis-salivarius-bacitracin and mitis-salivarius agar; (2) non-mutans str
38   Pretreatment with antibiotics (vancomycin, bacitracin and neomycin) in the drinking water for five
39             In the presence of extracellular bacitracin and nisin, respectively, the two response reg
40 cell wall biosynthesis such as moenomycin A, bacitracin and ramoplanin were not inducers of the S. co
41 es further demonstrated that aminoglycoside, bacitracin and sulfonamide resistance genes were express
42                             By comparing the bacitracin and the vancomycin stimulons, we can differen
43 entiate between loci induced specifically by bacitracin and those that are induced by multiple cell w
44 genes encoding resistance to the antibiotics bacitracin and vancomycin.
45 s that were fed chlortetracyline, tylosin or bacitracin and were land applied via broadcast, incorpor
46 ies have addressed the environmental fate of bacitracin and zinc-bacitracin complexes.
47 y limit the clinical use of fusidic acid and bacitracin and, possibly, rifaximin if resistance to thi
48 owing exposure to the antimicrobial peptides bacitracin and/or lysozyme.
49  (5,5'-dithiobis[2-nitrobenzoic acid]), (ii) bacitracin, and (iii) anti-PDI antibodies--resulted in r
50 -5'5-dithio-bis(2-nitrobenzoic acid) (DTNB), bacitracin, and anti-protein disulfide isomerase antibod
51 ar and OF basal medium with agar, polymyxin, bacitracin, and lactose) and by plating on antibiotic-co
52 eractions using the antibiotics polymyxin B, bacitracin, and meropenem.
53 resistance to trimethoprim, aminoglycosides, bacitracin, and polymyxin.
54 to target genes that are strongly induced by bacitracin, and the corresponding histidine kinases shar
55 UAB33 was identified as a potent producer of bacitracin B1 (UB1), exhibiting strong activity against
56                      The peptidyl antibiotic bacitracin (Bc) is one of the most widely used antibioti
57 esistance to antibiotics such as acriflavin, bacitracin, bleomycin, daunorubicin, florfenicol, and ot
58                      The inhibitors DTNB and bacitracin blocked the detection of these free thiols.
59 sesquioleate, benzalkonium chloride-neomycin-bacitracin, bronopol-methylchloroisothiazolinone-methyli
60 elerated factor Xa generation was blocked by bacitracin but not influenced by inhibition of vicinal t
61 bility was also increased to cycloserine and bacitracin, but not to fosfomycin or valinomycin; these
62               Direct and specific binding of bacitracin by BceB was demonstrated by surface plasmon r
63 d to a model in which BceAB protects against bacitracin by transfer of the target, C55 -PP, rather th
64 ophobic side chains align on one face of the bacitracin-C(55)PP complex, presumably interacting with
65                                              Bacitracin caused an unusual time-dependent opposing eff
66 he determination of polypeptide antibiotics (bacitracin, colistin, and polymyxin B) in muscle samples
67 tomy-tube otorrhea to receive hydrocortisone-bacitracin-colistin eardrops (76 children) or oral amoxi
68 ficantly higher sensitivity of the mutant to bacitracin compared with that of the parental strain.
69 ant and a yvcK mutant were more sensitive to bacitracin compared with the WT strain.
70 he environmental fate of bacitracin and zinc-bacitracin complexes.
71 s study, the photochemical transformation of bacitracin components (i.e., cyclic dodecapeptides) in t
72 ese results provide insight into the fate of bacitracin components in the aquatic environment and hig
73 ochemical degradation kinetics of individual bacitracin components, investigation of the relative con
74 peptides (vancomycin, ristocetin), peptides (bacitracin, cycloserine), and chloramphenicol were found
75 ioactive such as the antibiotics vancomycin, bacitracin, daptomycin and the beta-lactam-containing pe
76 COL2525 protein showed 87% homology with the bacitracin drug transporter BcrA of Staphylococcus homin
77 e synthesis of antibiotics of the gramicidin/bacitracin family; however, no bacteriophage genomes are
78 he white petrolatum group vs 4 (0.9%) in the bacitracin group (95% confidence interval for difference
79  due to Staphylococcus aureus vs none in the bacitracin group (P=.004).
80 in the white petrolatum group and 444 in the bacitracin group were evaluable for clinical response.
81                                              Bacitracin had no deleterious effect on HPV16 entry, cap
82 in the endosomal penetration of L2/vDNA, but bacitracin had no effect on gamma-secretase activity, in
83               Several different analogues of bacitracin have also been isolated or prepared, and the
84                            IDE inhibition by bacitracin impaired amylin degradation, increased amyloi
85 companied by any zone of inhibition around a bacitracin-impregnated disk, respectively.
86                      Inhibition of PDI using bacitracin increased aggregate production, even in wild
87                                              Bacitracin induced expression of bcrC, and this inductio
88          A systematic mutational analysis of bacitracin-induced genes led to the identification of a
89 sO transcription unit was under control of a bacitracin-inducible promoter.
90                            The IDE inhibitor bacitracin inhibited amylin degradation by 78% and insul
91 le IDE protein extracted from liver, or with bacitracin inhibited VZV infection.
92                                              Bacitracin is a macrocyclic peptide antibiotic that is w
93                                              Bacitracin is a metalloantibiotic agent that is widely u
94                                              Bacitracin is a mixture of nonribosomal peptides (NRPs)
95                                              Bacitracin is a widely used metal-dependent peptide anti
96 bition by dansylcadaverine, methylamine, and bacitracin is not due to an alkalinization of the lysoso
97 ng key non-ribosomal peptides (NRPs) such as bacitracin, lichenysin, and bacillibactin.
98 ing those that confer resistance to cadmium, bacitracin, macrolides, penicillin, kanamycin, and strep
99 and therapeutic (200 g/ton) concentration of bacitracin methylene disalicylate (BMD) to commercial tu
100 racin A(1), the most potent component of the bacitracin mixture, binds to Co(II) via the His-10 imida
101       The compensatory regulation within the bacitracin network can also explain how gene expression
102 e effects of the commonly used PDI inhibitor bacitracin on HPV16 infection.
103                Infusion of the PDI inhibitor bacitracin or a blocking monoclonal antibody against PDI
104 bitors of protein disulfide isomerase (PDI), bacitracin or antibodies to PDI.
105 MR categories were disseminated exclusively (bacitracin) or primarily (aminoglycoside, MLS and sulfon
106 ited by p-chloromercuribenzenesulfonic acid, bacitracin, or anti-PDI antibodies, these inhibitors had
107 sms, the BcrABC transporter, which pumps out bacitracin, or BacA, an undecaprenol kinase that provide
108 itis vs 4 patients (0.9%) in the group using bacitracin (P=.12).
109 identification of oxidative modifications in bacitracin photoproducts.
110 antibiotics), and three peptide antibiotics (bacitracin, polymyxin B, and vancomycin).
111 eptide antibiotics (gramicidin, actinomycin, bacitracin, polymyxins).
112 citracin transport permease, is an important bacitracin resistance determinant.
113                                     The bcrC bacitracin resistance gene, which is under the dual cont
114                                              Bacitracin resistance is normally conferred by either of
115 e suggest that this active redundancy in the bacitracin resistance network of B. subtilis is a genera
116 both YqjL, a putative hydrolase, and BcrC, a bacitracin resistance protein, were involved in PQ resis
117  signaling pathway in more detail, using the bacitracin resistance system BceRS-BceAB of Bacillus sub
118 ) and BceAB (an ABC transporter that confers bacitracin resistance).
119 This study reveals a direct role of LiaIH in bacitracin resistance, provides novel insights into the
120 AB) and secondary (BcrC and LiaIH) layers of bacitracin resistance.
121 ced genes led to the identification of a new bacitracin-resistance determinant, bceAB, encoding a put
122 n of undecaprenyl pyrophosphate recycling by bacitracin resulted in a similar decrease in the membran
123                                      Despite bacitracin's broad use, the molecular details of its tar
124                                              Bacitracin's efficient sequestration of its target repre
125                Genetic studies indicate that bacitracin sensitivity is due to accumulation of C35 -PP
126                             In addition, the bacitracin sensitivity of strains in which YvcK Thr-304
127                                              Bacitracin sensitivity results from impairment of the Bc
128 utant disruption of ytpB no longer increases bacitracin sensitivity.
129 nthesis, including ramoplanin, moenomycin A, bacitracin, several glycopeptides and some beta-lactams.
130  was able to partially rescue the virus from bacitracin, suggesting the involvement of a cellular red
131 s (RiPP) clusters, was elucidated to enhance bacitracin synthesis.
132                             Mechanistically, bacitracin targets bacteria by specifically binding to t
133 ts, from early modern medicines (penicillin, bacitracin) to current blockbuster drugs (cubicin, vanco
134 btilis bcrC (ywoA) gene, encoding a putative bacitracin transport permease, is an important bacitraci
135 sis of the global transcriptional profile of bacitracin-treated cells reveals a response orchestrated
136                                              Bacitracin treatment markedly increased staining at all
137 mportance as exemplified by peptides such as bacitracin, vancomycin, and daptomycin.
138 tidrug, macrolide-lincosamide-streptogramin, bacitracin, vancomycin, beta-lactam and aminoglycoside r
139                                              Bacitracin was rapidly taken up by host cells and coloca
140 for vancomycin, tunicamycin, flavomycin, and bacitracin were 1.1 microM, 0.01 microg/ml, 0.03 microg/
141 r the natural product, these next-generation bacitracins were found to form stable complexes with C(5
142 a sigM mutant was fourfold more sensitive to bacitracin, while the sigX mutant was only slightly sens
143                           In comparison with bacitracin, white petrolatum possesses an equally low in
144                                              Bacitracin with amylin caused a dramatic decrease in cel

 
Page Top